RAP variants for drug delivery and methods of use thereof
The present invention relates to stabilized RAP variants and methods of use thereof. Conjugates of stabilized RAP variants to therapeutic compounds and stabilized RAP fusion proteins comprising therapeutic polypeptides are also presented.
1. A composition comprising a domain 3 Receptor Associated Protein (RAP),
wherein one or more of the histidines of the domain is replaced with a hydrophobic residue selected from the group consisting of Phe, Val, Leu, Ile and Trp.
2. The composition of claim 1 , wherein the domain 3 RAP is a full-length RAP.
3. The composition of claim 1 , wherein the domain 3 RAP is less than a full-length RAP.
4. The composition of claim 3 , wherein the domain 3 RAP consists of domain 3 of RAP.
5. The composition of claim 1 , wherein at least one of the hydrophobic residues interacts with a protein of the low density lipoprotein receptor family of proteins (LDLRFP), when RAP is bound to the protein of the LDLRFP.
6. The composition of claim 5 , wherein the protein of the LDLRFP is low-density lipoprotein receptor-related protein 1 (LRP1).
7. The composition of claim 1 , wherein at least one of the histidines is replaced with a phenylalanine.
8. The composition of claim 7 , wherein
a) His 257, His 259, His 268, or His 290 is replaced by Phe,
b) His 257 and His 259 are replaced by Phe,
c) His 268 and His 290, are replaced by Phe, or
d) His 257, His 259, His 268 and His 290 are replaced by Phe.
9. The composition of claim 1 , wherein the domain 3 RAP is conjugated to a therapeutic compound.
10. The composition of claim 1 , wherein the domain 3 RAP is fused to a therapeutic polypeptide to produce a fusion peptide.
11. A method for transporting a therapeutic compound into a target cell comprising contacting the target cell with the composition of claim 9 .
12. A method for transporting a therapeutic polypeptide into a target cell comprising contacting the target cell with the fusion peptide of claim 10 .
13. A method for attenuating activity of a cell expressing one or more proteins of the LDLRFP in a subject comprising administering to a subject an effective amount of a composition of claim 1 .
14. The method of claim 13 , wherein the protein of the LDLRFP is LRP1.
15. A method for treating a solid tumor in a subject comprising administering to a subject an effective amount of a composition of claim 1 to treat the cancer.
16. A method for treating osteoporosis in a subject comprising administering to a subject an effective amount of a composition of claim 1 to treat the bone disorder.